MDLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medline Inc (MDLN) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown strong revenue growth in its latest quarter and received positive analyst ratings with raised price targets, the recent FDA warning and declining net income, EPS, and gross margin raise concerns. Additionally, the technical indicators suggest a neutral trend, and options data indicates bearish sentiment in the short term. Given the investor's preference for long-term investments, it would be prudent to wait for more clarity on the FDA issue and the upcoming Q1 financial results before making a decision.
The MACD is positively expanding, indicating bullish momentum. However, the RSI is in the neutral zone at 70.873, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 45.398), with limited upside in the short term.
Strong Q4 revenue growth of 14.78% YoY.
Positive analyst sentiment with multiple raised price targets and Buy ratings.
Launch of the Pick Pack Pro automated fulfillment system, which could enhance operational efficiency.
FDA warning regarding production violations, which could lead to regulatory action and financial penalties.
Declining net income (-37.02% YoY), EPS (-36.36% YoY), and gross margin (-9.56% YoY) in Q4
Bearish short-term stock trend with an 80% chance of a -10.02% decline over the next month.
In Q4 2025, revenue increased by 14.78% YoY to $7.79 billion. However, net income dropped by 37.02% YoY to $182 million, EPS fell by 36.36% YoY to $0.14, and gross margin decreased by 9.56% YoY to 22.32%.
Analysts are generally positive on MDLN, with multiple firms raising price targets (ranging from $47 to $60) and maintaining Buy or Outperform ratings. Analysts highlight strong revenue growth, margin expansion potential, and a compelling setup for fiscal 2026.
